Moleculin granted Australian patent for Annamycin lyophilizate; term until 2040

Moleculin Biotech, Inc.

Australian Patent No. 2024203598 covers preliposomal Annamycin lyophilizates with improved stability and high purity.
Base patent term extends to June 2040, subject to extension for regulatory approval.
Patent family includes issued U.S., allowed European, and expected Canadian patents.
Annamycin (naxtarubicin) has Fast Track & Orphan Drug designations from FDA for AML and STS lung mets, and EMA Orphan Drug for AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.